Increased Microvessel Density in Mucinous Compared with Malignant Serous and Benign Tumours of the Ovary

Overview

Journal Br J Cancer

Specialty Oncology

Date 1998 Jul 2

PMID 9649134

Citations 12

Authors

M Orre

M Lotfi-Miri

P Mamers

P A Rogers

Affiliations

Soon will be listed here.

Abstract

Microvessel density of benign, borderline and malignant ovarian tumours was studied immunohistochemically using antibodies to the endothelial cell markers CD31, CD34 and factor VIII-related antigen. Microvessel density was compared in tumours of different histological subtype, stage and patient outcome. CD31-immunostained sections were examined and regions of high and average microvessel density were selected. Identical regions were located on CD34- and factor VIII-related antigen-immunostained serial sections and microvessel counts obtained and converted to vessels mm(-2). CD31 and CD34 immunostaining revealed increased microvessel density in both the high and average vessel density regions of mucinous (222.4 +/- 24.8; 79.9 +/- 8.5) compared with serous (105.4 +/- 20.7; 33.3 +/- 6.8) and benign (84.4 +/- 19.4; 20.4 +/- 4.4) tumours (P < 0.001). CD31 and CD34 immunostaining also revealed increased microvessel density in early-stage mucinous tumours (234.6 +/- 28.2; 87.8 +/- 9.2) compared with that observed in both early- (72.8 +/- 15; 12.9 +/- 2.4) and late- (115.6 +/- 26.5; 29.8 +/- 8.5) stage serous tumours (P < 0.001). No differences in microvessel density in samples from patients with differing outcomes were observed (P > 0.05). Reduced factor VIII-related antigen compared with CD31 and CD34 immunostaining was observed in both borderline and malignant mucinous and serous tumours (P < 0.02) but not in benign tumours (P > 0.05). Our results contradict the putative association between increased microvessel density and poor prognosis and suggest that the level and control of angiogenesis may differ between ovarian tumour types.

Citing Articles

The Development of a Three-Dimensional Platform for Patient-Derived Ovarian Cancer Tissue Models: A Systematic Literature Review.

Sevinyan L, Gupta P, Velliou E, Madhuri T Cancers (Basel). 2022; 14(22).

PMID: 36428724 PMC: 9688222. DOI: 10.3390/cancers14225628.

Assessment of solid components of borderline ovarian tumor and stage I carcinoma: added value of combined diffusion- and perfusion-weighted magnetic resonance imaging.

Kim S Yeungnam Univ J Med. 2019; 36(3):231-240.

PMID: 31620638 PMC: 6784647. DOI: 10.12701/yujm.2019.00234.

Clinical significance of melanoma cell adhesion molecule CD146 and VEGFA expression in epithelial ovarian cancer.

Zhou P, Xiong T, Chen J, Li F, Qi T, Yuan J Oncol Lett. 2019; 17(2):2418-2424.

PMID: 30675307 PMC: 6341705. DOI: 10.3892/ol.2018.9840.

Reliability of preoperative evaluation of postmenopausal ovarian tumors.

Niemi R, Saarelainen S, Luukkaala T, Maenpaa J J Ovarian Res. 2017; 10(1):15.

PMID: 28288666 PMC: 5348789. DOI: 10.1186/s13048-017-0309-4.

Expression of a novel endothelial marker, C-type lectin 14A, in epithelial ovarian cancer and its prognostic significance.

Priya S, Kumar K, Hiran K, Bindhu M, Nagare R, Vijaykumar D Int J Clin Oncol. 2016; 22(1):107-117.

PMID: 27567920 DOI: 10.1007/s10147-016-1033-6.

References

Liotta L, KLEINERMAN J, Saidel G . Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res. 1974; 34(5):997-1004. View

Kristensen G, Trope C . Epithelial ovarian carcinoma. Lancet. 1997; 349(9045):113-7. DOI: 10.1016/S0140-6736(96)06071-0. View

Liotta L, Steeg P, Stetler-Stevenson W . Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991; 64(2):327-36. DOI: 10.1016/0092-8674(91)90642-c. View

Schlingemann R, Rietveld F, Kwaspen F, van de Kerkhof P, de Waal R, Ruiter D . Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissue. Am J Pathol. 1991; 138(6):1335-47. PMC: 1886404. View

Sheid B . Angiogenic effects of macrophages isolated from ascitic fluid aspirated from women with advanced ovarian cancer. Cancer Lett. 1992; 62(2):153-8. DOI: 10.1016/0304-3835(92)90186-y. View

Kuzu I, Bicknell R, Harris A, Jones M, Gatter K, Mason D . Heterogeneity of vascular endothelial cells with relevance to diagnosis of vascular tumours. J Clin Pathol. 1992; 45(2):143-8. PMC: 495659. DOI: 10.1136/jcp.45.2.143. View

Toi M, Kashitani J, Tominaga T . Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer. 1993; 55(3):371-4. DOI: 10.1002/ijc.2910550305. View

Fay P . Factor VIII structure and function. Thromb Haemost. 1993; 70(1):63-7. View

Reynolds K, Farzaneh F, COLLINS W, Campbell S, Bourne T, Lawton F . Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor. J Natl Cancer Inst. 1994; 86(16):1234-8. DOI: 10.1093/jnci/86.16.1234. View

10.

Dameron K, Volpert O, Tainsky M, BOUCK N . Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 1994; 265(5178):1582-4. DOI: 10.1126/science.7521539. View

11.

DeLisser H, Newman P, Albelda S . Molecular and functional aspects of PECAM-1/CD31. Immunol Today. 1994; 15(10):490-5. DOI: 10.1016/0167-5699(94)90195-3. View

12.

Visscher D, Lawrence W, BOMAN S . Angiogenesis in breast carcinoma--clinicopathologic relevance and potential use as a quantifiable surrogate endpoint biomarker. J Cell Biochem Suppl. 1994; 19:146-52. View

13.

Chaubal A, Paetau A, Zoltick P, Miettinen M . CD34 immunoreactivity in nervous system tumors. Acta Neuropathol. 1994; 88(5):454-8. DOI: 10.1007/BF00389498. View

14.

Fujita M, Enomoto T, Inoue M, TANIZAWA O, Ozaki M, Rice J . Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary. Jpn J Cancer Res. 1994; 85(12):1247-56. PMC: 5919385. DOI: 10.1111/j.1349-7006.1994.tb02937.x. View

15.

Rak J, St Croix B, Kerbel R . Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs. 1995; 6(1):3-18. DOI: 10.1097/00001813-199502000-00001. View

16.

Hollingsworth H, Kohn E, Steinberg S, Rothenberg M, Merino M . Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol. 1995; 147(1):33-41. PMC: 1869875. View

17.

Weidner N . Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol. 1995; 147(1):9-19. PMC: 1869874. View

18.

van Diest P, Zevering J, Zevering L, Baak J . Prognostic value of microvessel quantitation in cisplatin treated FIGO 3 and 4 ovarian cancer patients. Pathol Res Pract. 1995; 191(1):25-30. DOI: 10.1016/S0344-0338(11)80918-0. View

19.

Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T . Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 1995; 55(20):4575-80. View

20.

McCulloch P, Choy A, Martin L . Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery. Lancet. 1995; 346(8986):1334-5. DOI: 10.1016/s0140-6736(95)92345-4. View